Suppr超能文献

单剂量静脉注射呋塞米后代偿期肝硬化患者肾功能的变化。

The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis.

作者信息

Assy Nimer, Kayal Mohib, Mejirisky Yoram, Gorenberg Miguel, Hussein Osamah, Schlesinger Sorina

机构信息

Liver Unit, Sieff Hospital, Safed, Israel.

出版信息

BMC Gastroenterol. 2006 Nov 29;6:39. doi: 10.1186/1471-230X-6-39.

Abstract

BACKGROUND

Patients with compensated Child-A cirrhosis have sub clinical hypovolemia and diuretic treatment could result in renal impairment.

AIM

To evaluate the changes in renal functional mass as reflected by DMSA uptake after single injection of intravenous furosemide in patients with compensated liver cirrhosis.

METHODS

Eighteen cirrhotic patients were divided in two groups; eight patients (group 1, age 56 +/- 9.6 yrs, Gender 5M/3F, 3 alcoholic and 5 non alcoholic) were given low intravenous 40 mg furosemide and ten other patients (group 2, age 54 +/- 9.9, Gender 6M/4F, 4 alcoholic and 6 non alcoholic) were given high 120 mg furosemide respectively. Renoscintigraphy with 100MBq Of Tc 99 DMSA was given intravenously before and 90 minutes after furosemide administration and SPECT imaging was determined 3 hours later. All patients were kept under low sodium diet (80mEq/d) and all diuretics were withdrawn for 3 days. 8-hours UNa exertion, Calculated and measured Creatinine clearance (CCT) were performed for all patients.

RESULTS

Intravenous furosemide increased the mean renal DMSA uptake in 55% of patients with compensated cirrhosis and these changes persist up to three hours after injection. This increase was at the same extent in either low or high doses of furosemide. (From 12.8% +/- 3.8 to 15.2% +/- 2.2, p < 0.001 in Gr I as compared to 10.6% +/- 4.6 to 13.5% +/- 3.6 in Gr 2, p < 0.001). In 8 patients (45%, 3 pts from Gr 1 and 5 pts from Gr 2) DMSA uptake remain unchanged. The mean 8 hrs UNa excretion after intravenous furosemide was above 80 meq/l and was higher in Gr 2 as compared to Gr 1 respectively (136 +/- 37 meq/l) VS 100 +/- 36.6 meq/l, P = 0.05). Finally, basal global renal DMSA uptake was decreased in 80% of patients; 22.5 +/- 7.5% (NL > 40%), as compared to normal calculated creatinine clearance (CCT 101 +/- 26), and measured CCT of 87 +/- 30 cc/min (P < 0.001).

CONCLUSION

A single furosemide injection increases renal functional mass as reflected by DMSA in 55% of patients with compensated cirrhosis and identify 45% of patients with reduced uptake and who could develop renal impairment under diuretics. Whether or not albumin infusion exerts beneficial effect in those patients with reduced DMSA uptake remains to be determined.

摘要

背景

代偿期Child - A级肝硬化患者存在亚临床血容量不足,利尿剂治疗可能导致肾功能损害。

目的

评估单次静脉注射速尿后,代偿期肝硬化患者中锝- 99m二巯丁二酸(DMSA)摄取所反映的肾实质功能变化。

方法

18例肝硬化患者分为两组;8例患者(第1组,年龄56±9.6岁,5男3女,3例酒精性肝病和5例非酒精性肝病)静脉注射低剂量40mg速尿,另外10例患者(第2组,年龄54±9.9岁,6男4女,4例酒精性肝病和6例非酒精性肝病)分别静脉注射高剂量120mg速尿。在注射速尿前及注射后90分钟静脉注射100MBq的锝- 99m DMSA进行肾闪烁显像,并于3小时后进行单光子发射计算机断层扫描(SPECT)成像。所有患者维持低钠饮食(80mEq/d),停用所有利尿剂3天。对所有患者进行8小时尿钠排泄、计算及测量肌酐清除率(CCT)。

结果

静脉注射速尿后,55%的代偿期肝硬化患者肾DMSA摄取平均值增加,且这些变化在注射后持续长达3小时。低剂量或高剂量速尿的增加程度相同。(第1组从12.8%±3.8%增至15.2%±2.2%,p<0.001;第2组从10.6%±4.6%增至13.5%±3.6%,p<0.001)。8例患者(45%,第1组3例,第2组5例)DMSA摄取无变化。静脉注射速尿后平均8小时尿钠排泄高于80meq/l,第2组高于第1组(分别为136±37meq/l)对100±36.6meq/l,P = 0.05)。最后,80%的患者基础总肾DMSA摄取降低;与正常计算的肌酐清除率(CCT 101±26)相比为22.5±7.5%(正常>40%),测量的CCT为87±30cc/min(P<0.001)。

结论

单次注射速尿可使55%的代偿期肝硬化患者肾实质功能增加,这由DMSA反映出来,并可识别出45%摄取减少且在利尿剂治疗下可能发生肾功能损害的患者。白蛋白输注对那些DMSA摄取减少的患者是否有有益作用仍有待确定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df5d/1702545/221858b492c5/1471-230X-6-39-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验